Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $20.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 7.13% to $20.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.6 million through Dec 2025, up 7.13% year-over-year, with the annual reading at $20.6 million for FY2025, 7.13% up from the prior year.
  • Non-Current Deffered Revenue hit $20.6 million in Q4 2025 for Xilio Therapeutics, down from $25.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $38.7 million in Q1 2025 to a low of $8.4 million in Q3 2024.